Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
KKR's earnings call highlights strategic growth, strong investment management fees, and expanding global partnerships. Despite some management vagueness, the overall sentiment is positive, with robust financial metrics, optimistic guidance, and strategic positioning in emerging markets and technologies. The Q&A section reinforced confidence in asset-based finance and long-term opportunities in private markets. These factors suggest a positive stock price movement.
Fee-related earnings (FRE) $0.98 per share, up 33% year-over-year for the 12-month period ended June 30, 2025, compared to June 30, 2024. This increase was driven by healthy management fee growth, strengthening in capital markets activities, and operating leverage.
Management fees $996 million, up 18% year-over-year. This growth was attributed to the activation of Americas XIV in Q2, broader fundraising initiatives, and continued deployment.
Total transaction and monitoring fees $234 million for the quarter. No year-over-year change or reasons provided.
Capital Markets transaction fees $200 million, with over half coming from activities in Europe. No year-over-year change or reasons provided.
Fee-related performance revenues $54 million, up 45% year-over-year. The growth was driven by performance allocation from the offshore Infrastructure K-Series vehicle.
Fee-related compensation 17.5% of revenues, consistent with the midpoint of the guided range. No year-over-year change or reasons provided.
Other operating expenses $172 million for the quarter. No year-over-year change or reasons provided.
FRE margin 69%, with a 360 basis point improvement year-over-year. This was driven by healthy management fee growth and operating leverage.
Insurance segment operating earnings $278 million, modestly ahead of the $250 million level discussed last quarter. No year-over-year change or reasons provided.
Strategic Holdings operating earnings $29 million for the quarter. No year-over-year change or reasons provided.
Realized performance income $419 million for the quarter. No year-over-year change or reasons provided.
Realized investment income $154 million for the quarter. No year-over-year change or reasons provided.
Private equity portfolio performance Up 5% in the quarter and 13% over the last 12 months. No reasons for the change provided.
Opportunistic real estate portfolio performance Up 3% in the quarter and 7% over the last 12 months. No reasons for the change provided.
Infrastructure portfolio performance Up 3% in the quarter and 14% over the last 12 months. No reasons for the change provided.
Credit portfolio performance Leverage credit composite up 2% in the quarter and 7% over the last 12 months. Alternative credit composite up 1% in the quarter and 9% over the last 12 months. No reasons for the change provided.
Capital deployed year-to-date $37 billion, with half deployed in Q2. No year-over-year change or reasons provided.
Unrealized carried interest $9.2 billion, up 30% year-over-year from $7.1 billion. This increase reflects the strength of the global portfolio.
Realized performance and investment income (last 12 months) $2.6 billion, up over 20% year-over-year. This growth was driven by monetization activities.
HealthCare Royalty Partners (HCR) Acquisition: KKR acquired a majority stake in HCR, a leader in biopharma royalty investing, with $3 billion in AUM. This acquisition expands KKR's life sciences footprint and complements its existing healthcare investments.
Asia Market Expansion: KKR has been active in Asia with investments in various sectors, including agriculture in Australia, financial services in Singapore, and energy storage in Korea. Asia AUM has grown to $75 billion, with private equity now less than half of the total.
Asset-Based Finance (ABF) Growth: KKR raised $6.5 billion for its second ABF fund, tripling the size of its predecessor. ABF AUM increased by 20% year-over-year to $75 billion, with a $6 trillion addressable market expected to grow to $9 trillion in four years.
Fee-Related Earnings (FRE) Growth: FRE per share increased by 33% year-over-year, with a 360 basis point improvement in FRE margin. Management fees grew by 18% year-over-year, driven by fundraising and deployment activities.
Insurance Segment Performance: Insurance operating earnings reached $278 million, exceeding expectations. Third-party capital commitments, including $2 billion from Japan Post Insurance, are expected to add $60 billion in fee-paying AUM.
Global Atlantic Strategy: KKR continues to integrate third-party capital into its insurance strategy, with $6 billion in third-party capital capacity. This approach supports capital-efficient growth and enhances returns.
Life Sciences Expansion: The acquisition of HCR aligns with KKR's strategy to grow in long-duration and perpetual capital markets, leveraging synergies with its existing healthcare investments.
Market Volatility and Uncertainty: The company acknowledges that volatility and uncertainty in the macroeconomic environment create challenges, even as they present opportunities.
Regulatory and Compliance Risks: The company operates in multiple jurisdictions, including Asia, Europe, and the U.S., which may expose it to varying regulatory and compliance risks.
Geopolitical Risks: The company's significant operations in Asia and other global markets expose it to geopolitical risks, which could impact its investments and operations.
Fundraising Challenges: Despite progress, the company faces challenges in raising capital in a volatile market environment, which could impact its ability to grow AUM.
Insurance Business Risks: The insurance segment's performance is tied to long-term liabilities and alternative investments, which may carry inherent risks, including market fluctuations and leverage concerns.
Strategic Execution Risks: The company’s expansion into new areas like biopharma royalty investing and alternative credit markets involves execution risks, including integration and achieving expected returns.
Supply Chain and Operational Risks: The company’s investments in infrastructure and real assets may face supply chain disruptions and operational challenges.
Insurance segment operating earnings: Expected to remain at the $250 million plus/minus level over the next few quarters.
All-in pretax ROE: Continues to approach the 20% level.
Deployment and monetization activity: Healthy pipeline for deployment in the second half of 2025 with $115 billion of uncalled capital. Direct line of sight to over $800 million of monetization-related revenue in the second half of 2025.
Asset-Based Finance (ABF) business: ABF market expected to grow from $6 trillion today to over $9 trillion in the next 4 years. KKR sees significant growth opportunities in this area.
Asia infrastructure strategy: Capital raising has begun, with expectations of strong demand based on historical success and Pan-Asian presence.
Wealth management products: Continued momentum with inflows tracking at or ahead of expectations. Plans to launch a real asset product in the future.
Insurance business: Focus on elongating and diversifying liabilities, with $2.5 billion of funding agreements issued recently. Expectation to continue activity in the longer duration parts of the FABN market.
Third-party capital for Global Atlantic: Approximately $6 billion of third-party capital capacity, translating to over $60 billion of additional fee-paying AUM once deployed.
Life sciences footprint expansion: Acquisition of a majority stake in HealthCare Royalty Partners (HCR), adding approximately $3 billion in largely perpetual AUM. HCR expected to enhance origination capacity across Global Atlantic and credit pools of capital.
2026 guidance: Confidence in achieving 2026 guidance across fundraising and core financial metrics, including FRE per share, TOE per share, and ANI per share.
Dividends and Interest Income: Realized performance income was $419 million and realized investment income was $154 million. These earnings were driven by a combination of public secondary sales and private transactions, as well as K-PRIME's annual crystallization alongside with dividends and interest income.
The earnings call highlights strong financial performance with record fundraising and investment, significant embedded gains, and a robust insurance segment. The Q&A section supports this with positive growth prospects in Asia, strong ROE projections, and confidence in achieving future targets. Despite some uncertainties in management responses, the overall sentiment remains positive, supported by optimistic guidance and strategic growth plans.
KKR's earnings call highlights strategic growth, strong investment management fees, and expanding global partnerships. Despite some management vagueness, the overall sentiment is positive, with robust financial metrics, optimistic guidance, and strategic positioning in emerging markets and technologies. The Q&A section reinforced confidence in asset-based finance and long-term opportunities in private markets. These factors suggest a positive stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.